Cardiff Lexington Business Summary

Cardiff Lexington Corp (CDIX) operates as a diversified healthcare holding company primarily focused on the acquisition and scaling of middle-market niche clinics specializing in orthopedics, spine care, and interventional pain management. The company generates revenue through its flagship subsidiary, Nova Ortho and Spine, LLC, which utilizes a lien-based medical model to provide diagnostic and surgical services to traumatic injury victims. This model relies on "Letters of Protection" (LOPs) to secure payment from future legal settlements, effectively insulating the firm from traditional Medicare and Medicaid reimbursement risks while maintaining high collection rates. As of early 2026, the company is executing an aggressive expansion strategy across Florida and Georgia, transitioning from a broad holding company to a specialized healthcare consolidator. Its primary competitors include AirSculpt Technologies, DocGo, and Surgery Partners, though Cardiff Lexington distinguishes itself through its specific focus on the fragmented, high-margin personal injury and uninsured patient markets. Leadership is spearheaded by Alex Cunningham, who serves as both Chairman and Chief Executive Officer following a strategic board consolidation in late 2025. Cunningham, who joined the firm in 2015, has over 25 years of experience in healthcare operations and has been the architect of the company’s pivot toward the orthopedic sector. He is supported by Matthew T. Shafer, CPA, who serves as Senior Vice President and Chief Financial Officer, bringing extensive expertise in public market compliance and financial reporting. The clinical direction is led by Dr. Kevin Fitzgerald, Chief Medical Officer and Managing Director of Nova Ortho and Spine. The company is currently advised by investment bank R.F. Lafferty & Co. as it pursues a Nasdaq Capital Market uplisting, a move supported by a board that includes Independent Director Gillard B. Johnson III, aimed at enhancing institutional visibility and capital access for future acquisitions.